Figure 2.

Affinity Specificity and Neutralizing Abilities of the Potent Neutralizing mAbs

(A) Neutralization potency measured by using a pseudotyped virus neutralization assay. Data for each mAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean ± SD. See also Figure S4.

(B) Neutralization potency measured by an authentic SARS-CoV-2 plaque reduction neutralizing test (PRNT) assay. Data for each mAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean ± SD. See also Figure S6.

(C) Characteristics of the neutralizing mAbs. IC₅₀ and IC₈₀ were calculated by using a four-parameter logistic curve fitting. K_D targeting RBD was measured by using SPR with a 1:1 binding model. The somatic hypermutation rate (SHM) was calculated by comparing DNA sequences of the heavy-chain variable regions (V, D, and J regions) to germline sequences using Igblast.

See also Figure S5.